Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Volume: 80, Issue: 10, Pages: 2017 - 2030
Published: May 15, 2020
Abstract
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for EGFR-mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to osimertinib in transgenic mouse models of EGFRL858R -induced lung adenocarcinoma and found that it is mediated largely through secondary mutations in EGFR-either C797S or L718V/Q. Analysis of circulating free...
Paper Details
Title
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Published Date
May 15, 2020
Volume
80
Issue
10
Pages
2017 - 2030
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.